Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0368120190490030238
Korean Circulation Journal
2019 Volume.49 No. 3 p.238 ~ p.248
Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry
Kim Sung-Hwan

Yun Sung-Cheol
Park Jin-Joo
Lee Sang-Eun
Cho Myeong-Chan
Chae Shung-Chull
Kang Seok-Min
Choi Dong-Ju
Yoo Byung-Su
Kim Kye-Hun
Oh Byung-Hee
Baek Sang-Hong
Abstract
Background and Objectives: Beta-blockers are indicated in patients with heart failure (HF) with reduced ejection fraction. However, their efficacy in patients with HF with preserved ejection fraction (HFpEF) is uncertain. We investigated the hypothesis that beta-blockers are associated with reduced adverse events in patients with HFpEF.

Methods: The Korea Acute Heart Failure (KorAHF) is a prospective observational multicentre cohort study. The 5,625 patients hospitalized for acute HF syndrome in 10 tertiary university hospitals across the country have been consecutively enrolled between March 2011 and February 2014. Of these patients, 2,152 patients with HFpEF (ejection fraction ¡Ã40%) were investigated. The primary outcome was all-cause mortality according to beta-blocker use.

Results: During a median follow-up duration of 807 days, 702 patients died. In Cox proportional hazards model beta-blocker use was associated with a 14% reduced all-cause death (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.75?0.98), but not with reduce rehospitalization (HR, 1.03; 95% CI, 0.85?1.27). In the propensity-score matched population, beta-blockers were also associated with reduced all-cause death (HR, 0.80; 95% CI, 0.69?0.94) but not with reduced rehospitalization (HR, 1.08; 95% CI, 0.87?1.33).

Conclusions: In Korean patients with HFpEF, use of beta-blockers is associated with reduced all-cause death but not with reduced rehospitalization.
KEYWORD
Adrenergic beta-antagonist, Heart failure, Diastole
FullTexts / Linksout information
  
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø